TORONTO, Feb. 6, 2012 /CNW/ - MedX Health Corp., (TSXV.MDX) announces its plan, subject to TSX Venture Exchange approval, to settle debts outstanding in the amount of $68,623.00. The company agrees to issue 686,230 common shares at $0.10 per common share. All securities issued in connection with the settlement are subject to a resale restriction for a period of four (4) months and 1 day from the date of issue.
About MedX Health Corp.
MedX is a global leader in both a drug free, non-invasive low level laser and light therapy for tissue repair and pain relief and skin imaging technologies. MedX Health Corp. acquired the worldwide assets of MoleMate (trademarks, IP, contracts) in June, 2011. MoleMate is a non-invasive, pain-free skin imaging device which uses light to look 2mm below the surface of the skin, enabling physicians to quickly scan suspicious moles, so they will be able to tell patients in an accurate and timely manner whether treatment is required, or reassure them that their mole is benign. MoleMate is FDA approved and has been sold to physicians in the European Community, the UK, Australia and the US. For more information go our website www.simsys-molemate.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
For further information: